Abstract
Purpose
To challenge the view that the dose of folinic acid rescue after high-dose methotrexate (MTX) has no significance in the prevention of neurotoxicity and to present the minority view that neurotoxicity can be prevented by an adequate dose of folinic acid, without compromising treatment results. Several fallacies that led to the misunderstanding of post MTX neurotoxicity are presented.
Methods
Data mining using search engines was used to find relevant publications, and an e-mail survey of more than 60 authors of articles in this field was performed. All relevant articles identified were read in their entirety.
Results
Examples of clinical studies with neurotoxicity following inadequate rescue are given. Some studies demonstrated no neurotoxicity when adequate doses of folinic acid rescue were started 24–36 h after the start of HDMTX rescue even after mega doses of MTX. Rescue started after 42 h was associated with neurotoxicity except in patients with low serum MTX levels after 24 and 36 h. ALL protocols with neurotoxicity, especially BFM-like protocols, are presented. Protocol is reported in which single protocol changes prevented neurotoxicity.
Conclusions
From the published data, when folinic acid rescue is given in a sufficiently high enough dose and is started 24–36 h after the beginning of the methotrexate exposure, and virtually all forms of post MTX neurotoxicity can be prevented without compromising therapeutic results.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Introduction
The data presented in the recent article by Krull et al. [1] present further support to those challenging the widely accepted view that the dose of the folinic acid (FA, leucovorin, LV, citrovorum factor) rescue after high-dose methotrexate (MTX) has no significance in the prevention of neurotoxicity. In addition, children treated on the ACCLO131 ALL (Acute lymphatic leukemia) protocols who received less folinic acid (P9605) were found to have more widespread neurocognitive late affects (82%) than those given more folinic acid (P 9201; 24%) [2]. The significant implication of these findings is to seriously challenge the trend of cooperative groups to continually reduce the folinic acid dose after MTX: “attention needs to be paid to the leucovorin rescue, keeping it to the minimum” [3]. Significantly, no studies have been published showing an improved prognosis with reduced folinic acid rescue. This question has become even more relevant now that high-dose MTX has been shown to be more effective than the Capizzi MTX element in the treatment of childhood acute lymphatic leukemia (ALL) [4].
The folinic acid dose is critical for preventing neurotoxicity after HDMTX
The vindication of the minority view that neurotoxicity after MTX is preventable with an adequate dose of folinic acid, without compromising treatment results, is long overdue. The opposite view has been accepted for over 50 years without supporting evidence [5] and with well-documented observations incompatible with this theory. In 1976, leukoencephalopathy was described following 5 mg/kg of monthly intravenous MTX [6]. If folinic acid rescue does not protect the brain it would not have been possible to give 15–20 g/m2 MTX, one hundred times this dose without neurotoxicity [7].
The basis of the misunderstanding of post MTX neurotoxicity
The belief that folinic acid is ineffective in post-MTX neurotoxicity is based on three misconceptions. This first fallacy is that “Although oral leucovorin may effectively rescue folate depleted cells outside the CNS, the levels of citrovorum factor achieved in the CNS are probably inadequate to rescue folate-depleted enzyme systems” [8]. However, folinic acid CSF levels have been shown to reach 2 × 10−7 M for short periods and then drop to 2 × 10−8 M after intravenous administration of 50 mg folinic acid [9]. This is not surprising given that MTX is part of a group of drugs prepared as analogs of folic acid and would, therefore, be expected to cross the blood–brain barrier in a manner similar to that of folic acid. The second fallacy is that “The administration of oral leucovorin raises the concentration of folate in the CSF and may selectively rescue cells in the CSF” [10]. This was recently disputed by a detailed analysis of the published literature [9]. The third fallacy is that since dihydrofolate reductase is absent from brain tissue, there is no substrate for the folinic acid [11]. Yet in 1978, dihydrofolate reductase was identified in both brain tissue [12] and human brain tumors [13]. A representative report from this period [14] stated that systemic toxicity from an overdose of intrathecal MTX (ITMTX) was prevented by folinic acid, but it did not mention the possibility that folinic acid could prevent MTX neurotoxicity. In subsequent reports of two patients with an overdose of ITMTX, one was rescued by high-dose folinic acid without neurotoxicity and the other had a fatal outcome after receiving a lower folinic acid dose [15, 16], but the authors failed to appreciate the significance of the folinic acid dose [5]. Indeed, reviews of MTX-associated neurotoxicity often do not even discuss folinic acid [17,18,19,20].
This issue is further complicated by the mistaken assumption that there is a linear relationship between the dose of MTX and the dose of folinic acid and a fixed MTX-folinic acid ratio is required for rescue. Higher doses of MTX require more than an equivalent increase in the dose of folinic acid, perhaps because higher doses of MTX promote the formation of more MTX polyglutamates than lower doses [21]. A double dose of MTX has been shown to require 3–4 times more folinic acid to prevent neurotoxicity [22]. Conversely when low dose MTX is used over rescue is not uncommonly reported [23].
Factors determining recovery of cell growth by folinic acid after MTX
A study of osteogenic sarcoma cell lines reported that cell growth was inhibited by adding 10−7 M MTX and restarted 12 h later with the supplementation of folinic acid that reached the 10−5 M level [24]. The effect of higher levels of MTX (10−6 and 10−5 M) was only partially reversed by higher levels of folinic acid (10−5 and 10−4 M) [24]. In mouse bone marrow cells, treatment with 10−3 M folinic acid failed to rescue the toxic effects of 10−4 MTX [25]. Effective folinic acid rescue cannot be expected until the plasma MTX level falls below 10−6 M [24]. When this does not occur because of renal shutdown, neutralizing MTX with carboxypeptidase may be required to prevent severe toxicity [26].
The effect of radiation on high dose neurotoxicity
No explanation had been proposed to explain why the risk of high-dose MTX-induced neurotoxicity increases when radiotherapy is delivered before, but not after, MTX [27]. Disruption of the blood–brain barrier by radiotherapy leads to higher MTX levels in the cerebrospinal fluid, warranting a higher dose of folinic acid rescue to prevent neurotoxicity [28]. This caveat, of course, is only relevant when radiotherapy is given prior to MTX.
Review of the literature on high-dose mtx and neurotoxicity
The citation index of the Web of Science Since lists more than 43,000 English language publications on MTX since 1965 making a full review impossible. The conclusions presented here are based on data mining using search engines to find relevant publications and an e-mail survey of more than 60 authors of articles in this field. The vast majority of authors were happy to cooperate and some also provided unpublished missing data. All the relevant articles identified were read in their entirety for clarity and to ensure that the conclusions reached were compatible with the data. Reviews and editorials were included but not publications presenting opinions based only on cited articles. A full report of the findings has been published elsewhere [9].
No evidence of folinic acid “over rescue” being a clinical problem after HDMTX
No convincing evidence was found that over rescue of malignant cells occurred in clinically relevant doses. Many articles cited to show the danger of folinic acid over rescue also supported the opposite view. “Progressive increase in the calcium leucovorum dosage on any schedule reduced both toxicity and the antitumor effect of methotrexate in each model” appears in the same article as “on certain schedules with methotrexate. Toxicity could virtually be eliminated with no diminution in antitumor efficiency [22]. A major confusion was caused by misunderstanding and misquoting of an article by Borsi et al. [29] (cited at least 30 times in the English language literature) that re-analyzed the doses of folinic acid that had been given as a milligram dose after 6–8 g/m2 of HD MTX in ALL and calculated the dose according to the surface area of the patient (from mg to mg/m2). The abstract reported that “reduction in the folinic acid dose to below the generally accepted 12–15 mg/m2 dose may increase the efficiency of high-dose MTX while remaining safe in preventing treatment-related toxicity.” On reading the whole article, it becomes clear that they were discussing the size of the dose of folinic acid given every 3 and 6 h not the total dose (that was between 158 and 588 mg/m2). In subsequent studies they reported administering at least 170 mg/m2 folinic acid after 6–8 g/m2 MTX [30]. Skarby et al. [31] were worried that relapse occurred more frequently when higher doses of FA rescue were used. They reported that more relapses had occurred in patients who had received higher folinic acid rescue doses in two of four groups. The significance of their interpretation is questionable since in the other two groups that were of a similar size, those who received the higher folinic acid doses had less relapses.
Determining adequate folinic acid rescue by protocol (Table 1)
Inadequate folinic acid rescue may occur as the result of using too low a dose of folinic acid and/or too great a delay in the start of rescue. Besides the dose of MTX used, the duration of the MTX infusion (which may be modified using a split regimen of an initial higher dose and a longer continuous dose) and the interval from the start of the MTX administration to the start of folinic acid administration and the folinic acid dose need to be taken into account. Additional important factors are the presence of renal damage caused by drugs such as cisplatin [45] and the concomitant use of certain drugs [46] that can modify serum MTX levels. Low doses of MTX given over a long time or in small repeated dose that maintain the serum level of 10−6 M MTX can cause toxicity especially neurotoxicity [9].The complexity of these factors is the basis for the need to examine the toxicity or lack of toxicity encountered with each different protocol.
Use of different MTX doses in different diseases
In vitro evidence suggests that longer exposure to therapeutic MTX levels is associated with more cytotoxicity than exposure to higher peak extracellular concentrations [47]. Protocols designed for childhood ALL are based on an accepted therapeutic serum MTX level of 10−6 M for at least 24 h. This is achieved by infusion of 6 g/m2 MTX over 24 h following an initial dose of 10% over the first hour or infusion of 5 g/m2 MTX and ITMTX. In a study of patients with osteogenic sarcoma, adjusting MTX levels to 2 × 10−5 M at 24 h and 10−6 M at 48 h followed by high-dose folinic acid led to some of the best results reported to date (high cure rate and absence of neurotoxicity on neuropsychological testing) [48]. In patients with pediatric brain tumors, CSF levels of 10−6 M were achieved by the administration of at least 5 gm/m2 MTX after radiotherapy or 10 g/m2 MTX without radiotherapy [49]. The improvement in outcome in patients with T cell ALL was attributed to the use of high-dose MTX [50]. The dose of MTX will affect the length of time a therapeutic level is achieved but no evidence was found that a higher MTX level is more effective than a lower level that prevents cell metabolism. No evidence has been found to support the use of different doses of folinic acid in different diseases.
Time of onset of folinic acid rescue
Many studies have demonstrated non neurotoxicity associated with the use of adequate doses of Folinic acid rescue started 24–36 h after the start of HDMTX rescue [51]. Rescue started after 42 h has been associated with evidence of neurotoxicity except in patients who had low serum MTX levels after 24 and 36 h.
Neurotoxicity in ALL protocols (Table 2)
Vermar et al. [60] claimed that significant neurotoxicity is observed in most high-dose MTX treatment protocols that include folinic acid rescue, which suggests that the usual doses of folinic acid are insufficient. Accordingly, Krull et al. [1] found that low-risk patients with ALL treated with 2.5 g/m2 MTX followed by 50–75 mg/m 2 folinic acid did less well than controls on 10 measures of neuropsychological function. The difference from controls was even more significant in the standard- risk/high-risk patients who received 5 g/m2 MTX with the same rescue protocol.
In the POG 8399 pilot study [37], 1 g/m2 MTX was administered over 24 h, and rescue was started at 48 h with 15 mg/m2 folinic acid every 6 h × 5 followed by 5 mg/m2 every 6 h × 5 (total 100 mg/m2). Of 83 children in the cohort, 6 (7%) had neurotoxicity (4 seizures, 2 transient paresis, 2 acquired leukoencephalopathy). In the subsequent POG 9005 trial [38], patients in Arm A were treated with 1 g/m2 MTX over 24 h and rescue at 48 h with 5 mg/m2 folinic acid every 6 h × 5. Grade 3–4 neurotoxicity was seen in 8.3% of the children (57% with leukoencephalopathy). Arm C patients were treated with MTX at the same doses as in Arm A and had an 11.2% rate of neurotoxicity. The POG 9405 protocol consisted of 1.0 or 2.5 g/m2 MTX followed at 48 h by 5 mg/m2 folinic acid every 6 h × 5 [39]. The study had to be terminated early because of the high neurotoxicity, including seizures, cognitive disturbances, ataxia, somnolence, calcifications on computed tomography scan, and leukoencephalopathy in both MTX dose groups. When the MTX dose was reduced to 1 g/m2 every 4 weeks instead of every 2 weeks and the folinic acid dose was doubled to 10 mg/m2 starting at 42 h, neurotoxicity apparently decreased, although the follow-up time was short [39].
Neurotoxicity in BFM-like protocols
The BFM group tend not to publish neurotoxicity data. Patients treated with the ALL-REZ BFM 90 protocol received 1 g/m2 MTX and 30 mg/m2 folinic acid or 5 g/m2 MTX plus intrathecal MTX and 45 mg/m2 folinic acid [58]. The authors seem to be unaware of reports of considerable neurotoxicity from groups that used BFM-based protocols or use similar doses of MTX and folinic acid. A neurotoxicity rate of 5.8% was reported a subgroup [33] of the AIEOP ALL 9102 trial [34] treated with 5 g/m2 MTX followed by 37.5 mg/m2 levo folinic acid (equivalent to 75 mg/m2 folinic acid [5]). In the AIEOP ALL 9502 protocol [33, 34] consisting of 2 g/m2 MTX followed by 15 mg/m2 levo folinic acid (equivalent to 30 mg folinic acid [5]), the neurotoxicity rate was 18.4%. Patients treated with the DCLSG ALL 8 and 9 protocols received 2, 3, or 5 g/m2 MTX over 24 h followed at 36–42 h by 45 mg/m2 folinic acid continued until a peak of <2.5 × 10−7 MTX was reached [35, 36, 42, 43]. All children showed attentional dysfunction and performed worse on 4 outcome measures of neuropsychological status than controls. The EORTC 5881 protocol consisted of 5 g/m2 MTX plus ITMTX over 24 h with folinic acid rescue starting at 36 h with 15 mg/m2 every 6 h until a peak of <2 × 10−7 MTX was achieved. The authors reported a reduction in 3 measures of cognitive function compared to controls [35, 36].
Protocols that avoided neurotoxicity with adequate folinic acid rescue
Some groups have avoided subtle neurotoxicity and neuropsychological dysfunction by using more folinic acid. No neurotoxicity was reported with the National Protocol 7, consisting of 5 g/m2 MTX followed by 210 mg/m2 folinic acid [41, 61] the MRC UKALL XI protocol, consisting of 6 or 8 g/m2 MTX over 24 h plus IT MTX followed at 36 h with folinic acid at a dose of 15 mg/m2 × 6 and then 15 mg/m2 every 6 h (the minimum dose of 75 mg/m2 folinic acid) until MTX level was 1 × 10−7 [62, 63]; and the LMB CNS lymphoma protocol, consisting of 8 g/m2 MTX and 180 mg/m2 folinic acid [64]. Others preceded high-dose MTX administration by intra-arterial mannitol to disrupt the blood–brain barrier and followed MTX administration with high-dose folinic acid (1080 mg in adults, 750 mg in children) [65], with no evidence that prognosis was compromised. This was also true for patients with osteosarcoma treated with high-dose folinic acid rescue after MTX [48]. Other studies of patients with osteosarcoma found that neurotoxicity was not correlated with the MTX dose [66] but it was correlated with the folinic acid rescue dose [67]. The patients who received 120–250 mg/m2 folinic acid (after 12–20 g/m2 MTX) had significantly lower scores on 12 neuropsychological tests than the patients who received 300–600 mg/m2 folinic acid [67].
Mega-dose MTX
In the treatment of ALL, there was no toxicity even after the administration of mega-doses of MTX (33.6 g/m2) when followed by high-dose folinic acid (272 mg/m2) [56, 57]. Similar findings were noted in a phase 1 trial in which 88 g/m2 MTX was administered followed by high-dose folinic acid [28].
Single protocol changes that reduced neurotoxicity
Single protocol changes that resulted in a reduction of neurotoxicity have special significance. The 19% neurotoxicity seen when 100 mg/m2 MTX was given with ITMTX or triple therapy was reduced to zero when 5 mg/m2 folinic acid was added at 48 and 60 h [6]. In this study, rescue was still possible after 48 h because of the low MTX dose [51]. Others found that when 2.5 g/m2 MTX was followed at 48 h by folinic acid at a dose of 15 mg/m2 × 6, there were 5 deaths and 16 cases of severe toxicity. However, no further toxicity occurred when rescue was started at 36 h [44]. One study reported unexpected acute neurotoxicity, including seizures and transient neurological deficits, in 6 of 42 children with ALL given a lower dose of oral MTX, 25 mg/m2 every 6 h × 4 every 4 weeks together with ITMTX 8, 10, or 12 mg according to age. Oral folinic acid 5 mg was administered at 24 h after ITMTX in the consolidation phase of therapy but not during the continuation phase. In the next group of 24 patients, however, an additional dose of 5 mg oral folinic acid was added at 36 h after IT MTX in consolidation, and there were no cases of neurotoxicity [10].
Over-rescue with mega-doses of folinic acid
Over-rescue after high-dose MTX with a mega dose of folinic acid (<900 mg/m2) was described in a mouse model. Animals were given 400 mg/kg MTX (equivalent to 12–15 g/m2) and rescued at 16 h with 400 mg/kg folinic acid (equivalent to 12,000 mg/m2). This resulted in a 2 log lower cell kill than rescue with 24 mg/kg folinic acid (equivalent to 700 mg/m2) [68]. The single clinical report of over-rescue after high-dose MTX involved a case of osteosarcoma tumor regrowth following treatment with 1275 mg (930 mg/m2) folinic acid after a second dose of MTX. Chemotherapy was changed to cisplatin, ifosfamide, and Adriamycin, but the resected lower femur still showed 10–15% viable tumor. Nevertheless, successful salvage was achieved with an additional 12 doses of high-dose MTX [69]. It should be appreciated that using mega-doses of folinic acid to prevent toxicity in the presence of very high, potentially toxic, serum levels of MTX after renal shut-down puts the patient at risk of death from tumor recurrence [70].
Upper limit of folinic acid rescue dose after HDMTX without over-rescue
Patients with osteosarcoma treated according to a protocol of 12.5–20 g/m2 MTX and 760 mg/m2 (max 760 mg) folinic acid showed no evidence of a reduced effect of chemotherapy [48] or of neurotoxicity on detailed neuropsychological investigation [67]. In another study, 930 mg/m2 (1275 mg) folinic acid administered to a patient with osteosarcoma resulted in over-rescue of malignant cells with tumor regrowth [69].
Future directions
The importance of neurotoxicity assessment in MTX-containing protocols
The term neurotoxicity has been used by different authors in different ways [9]. The recent COG AALL0232 study included only seizures and strokes in the neurtotoxicity report [4], and the NOPHO 2008 study included only seizures, coma and posterior reversible encephalopathy syndrome (PRES) [71]. This is no longer adequate. To fully assess the neurotoxicity associated with MTX-containing protocols, it is crucial that data derived from a neuropsychological assessment of different aspects of neurocognitive behavior be presented as an integral part of the treatment results.
A detailed validated neuropsychological assessment that tests different aspects of neurocognitive behavior should be adopted as the gold standard [72].
Adequate doses of folinic acid rescue starting 24–36 h after start of MTX
The appropriate dose of folinic acid to prevent neurotoxicity for each dose of MTX has been derived from the published literature [5]. However, clinicians should be aware that reports of the folinic acid doses associated with neurotoxicity are more reliable than reports that found no neurotoxicity because the latter studies may not have looked specifically for subtle evidence of neurotoxicity by neuropsychological testing. Thus, it was possible to define inadequate doses of folinic acid but future dose recommendations may be even higher than those suggested here (Table 3).
Cooperation between cooperative groups to investigate the toxicity associated with different protocols
The NOPHO ALL 1992 study administered 5 g/m2 MTX followed at 42 h by 45 mg/m2 folinic acid. The subsequent NOPHO 2000 and 2008 protocols used 5 gm/m2 MTX + ITMTX and reduced the folinic acid to a minimum of 30 mg/m2 starting at 42 h or 8 g/m2 MTX followed by a minimum folinic acid dose of 60 mg/m2. The Ponte di Legno toxicity working group is currently conducting a neurotoxicity analysis of the NOPHO 2008 protocol and a neurotoxicity substudy in the UKALL 2011 study that includes patients randomized to receive MTX 5 g/m2 with a rescue similar to the NOPHO protocols (personal communications from Dr. Arja Harila–Saari, Dr. Kjeld Smiegelow and Dr. Christina Halsey.)
Conclusion
There is much to recommend starting folinic acid rescue at 36 h after starting of MTX in order to simplify the rescue protocol. Rescue is possible even after 42 h in some situations but increases the danger of neurotoxicity. According to the published data, when the folinic acid rescue is given in a sufficiently high enough dose and is started 24–36 h after the beginning of the methotrexate exposure, virtually all forms of post MTX neurotoxicity can be prevented without compromising therapeutic results. Some seem upset by this interpretation of the data. “You will not change the way we treat our children” was the comment of one anonymous reviewer. I hope this is not so.
Abbreviations
- ALL:
-
Acute lymphoblastic leukemia
- ITMTX:
-
Intrathecal methotrexate
- HDMTX:
-
High dose methotrexate
- MTX:
-
Methotrexate
- FA:
-
Folinic acid
References
Krull K, Cheung YT, Liu W, Fellah S, Reddick WE, Brinkman TM, Kimberg C, Ogg R, Srivastava D, Pui CH, Robison LL, Hudson MM (2016) Chemotherapy pharmacodynamics and neuroimaging and neurocognitive outcomes in long-term survivors of childhood acute lymphoblastic leukemia. J Clin Oncol 34:2644–2653
Duffner PK, Armstrong FD, Chen L, Helton KJ, Brecher ML, Bell B, Chauvenet AR (2014) Neurocognitive and neuroradiologic central nervous system late effects in children treated on pediatric oncology group (POG) P9605 (standard risk) and P9201 (lesser risk) acute lymphoblastic leukemia protocols (ACCL0131): a methotrexate consequence? A report from the Children’s Oncology Group. J Pediatr Hematol Oncol 36:8–15
Richards S, Pui CH, Gayon P, Childhood Acute Lymphoblastic Leukemia Collaborative Group (CALLCG) (2004) Systemic review and meta-analysis of randomized trials of central nervous system directed therapy for childhood acute lymphoblastic leukemia. Pediatr Blood Cancer 60:185–195
Larsen EC, Devidas M, Chen S et al (2016) Dexamethasone and high-dose methotrexate improve outcome for children and young adults with high-risk b-acute lymphoblastic leukemia: a report from Children’s Oncology Group Study AALL0232. J Clin Oncol 34:2380–2388
Cohen IJ (2004) Defining the appropriate dosage of folinic acid after high-dose methotrexate that will prevent neurotoxicity without rescuing malignant cells in the central nervous system. J Pediatr Hematol Oncol 26:156–163
Meadows AT, Evans AE (1976) Effects of chemotherapy on the central nervous system: a study of parental methotrexate in long term survivors of leukemia and lymphoma in childhood. Cancer 21:1079–1085
Cohen IJ, Vogel R, Matz S, Weitz R, Mor C, Stern S, Zaizov R (1986) Successful non - neurotoxic therapy (without radiation) of a multifocal primary brain lymphoma with a methotrexate, vincristine and BCNU protocol (DEMOB). Cancer 57:6–11
Allen JC, Rosen G, Mehta BM, Horten B (1980) Leukoencephalopathy following high-dose iv methotrexate chemotherapy with leucovorin rescue. Cancer Treat Rep 64:1261–1273
Cohen IJ (2013) Challenging the clinical relevance of folinic acid over rescue after high dose methotrexate (HDMTX). Med Hypotheses 81:942–947
Winik NJ, Bowman WP, Kamen BA, Roach ES, Rollins N, Jacaruso D, Buchanan GR (1992) Unexpected acute neurotoxicity in the treatment of children with acute lymphatic leukemia. J Natl Cancer Inst 84:252–256
Makulu DR, Smith EF, Bertino JR (1973) Lack of dihydrofolate reductase activity in brain tissue of mammalian species: possible implications. J Neurochem 21:241–245
Pollock RJ, Kaufman S (1978) Dihydrofolate reductase is present in brain. J Neurochem 30:253–256
Abelson HT, Fosburg M, Gorka C, Kornblith P (1978) Identification of dihydrofolate reductase in human central-nervous-system tumours. Lancet 1:184–185
Lampkin BC, Higgins GR, Hammond D (1967) Absence of neurotoxicity following massive intrathecal administration of methotrexate. Cancer 20:1780–1781
Spiegel RJ, Cooper PR, Blum RH, Speyer JL, McBride D, Mangiardi J (1984) Treatment of massive intrathecal methotrexate overdose by ventriculolumbar perfusion. N Eng J Med 311:386–388
Ettinger LJ (1982) Pharmacokinetics and biochemical effects of a fatal intrathecal methotrexate overdose. Cancer 50:444–450
Abelson HT (1978) Methotrexate and central nervous system toxicity. Cancer Treat Rep 62:1999–2001
Shapiro WR, Allen JC, Horten B (1980) Chronic methotrexate toxicity to the central nervous system. Clin Bull 10:49–52
Reddick WE, Glass JO, Helton KJ, Langston JW, Xiong X, Wu S, Pui CH (2005) Prevalence of leukoencephalopathy in children treated for acute lymphoblastic leukemia with high-dose methotrexate. AJNR Am J Neuroradiol 26:1263–1269
Waber DP, Tarbell NJ, Kahn CM, Gelber RD, Sallan SE (1992) The relationship of sex and treatment modality to neuropsychologic outcome in childhood acute lymphoblastic leukemia. J Clin Oncol 10:810–817
Bleyer WA (1989) New vistas for leucovorin in cancer chemotherapy. Cancer 63:995–1007
Sirotnak FM, Moccio DM, Dorick DM (1978) Optimization of high-dose methotrexate and leucovorin rescue therapy in the L1210 leukemia and sarcoma 180 murine tumor models. Cancer Res 38:345–353
Browman GP, Goodyear MDE, Levine MN, Russell R, Archibald SD, Young JEM (1990) Modulation of the antitumor effect of methotrexate by low-dose leucovorin in squamous cell head and neck cancer: a randomized placebo-controlled clinical trial. J Clin Oncol 8:203–208
Diddens H, Teufel T, Neithammer D (1978) High dose methotrexate therapy with leucovorin rescue. In vitro investigations on human osteosarcoma cell lines. Cancer Chemother Pharmacol 20:128–132
Pinedo HM, Zaharko DS, Bull MB, Chabner BA (1976) The reversal of methotrexate cytotoxicity to mouse bone marrow cells by leucovorin and nucleosides. Cancer Res 36:4418–4424
Svahn T, Mellgren K, Harila-Saari A, Åsberg A, Kanerva J, Jónsson Ó, Vaitkeviciene G, Stamm Mikkelssen T, Schmiegelow K, Heldrup J (2016) Delayed elimination of high dose methotrexate and use of carboxypeptidaseG2 in pediatric patients during treatment for acute lymphatic leukemia. Pediatr Blood Cancer. doi:10.1002/pbc.26395
Allen CA, Walker R, Rosen G (1988) Preradiation high dose intravenous methotrexate with leucovorin rescue for untreated childhood brain tumors. J Clin Oncol 6:649–653
Cohen IJ (2007) Prevention of high-dose-methotrexate neurotoxicity by adequate folinic acid rescue is possible even after central nervous system irradiation. Med Hypotheses 68:1147–1153
Borsi JD, Wesenberg F, Stockland T, Moe PJ (1991) How much is too much? folinic acid rescue dose in children with acute lymphatic leukemia. Eur J Cancer 27:1006–1009
Seidel H, Moe PJ, Nygaard R, Nygaard K, Brede W, Borsi JD (1994) Evaluation of serious events in patients treated with protocols including methotrexate infusions. Pediatr Hematol Oncol 11:165–172
Skarby T, Anderson H, Heldrup J, Kanerva JA, Seidel H, Schmiegelow K, Nordic Society of Paediatric Haematology and Oncology (NOPHO) (2006) High leucovorin doses during high dose methotrexate treatment may reduce the cure rate in childhood acute lymphatic leukemia. Leukemia 20:1955–1962
Vezmar S, Schüsseler P, Becker A, Bode U, Jaehde U (2009) Methotrexate-associated alterations of the folate and methyltransfer pathway in the CSF of ALL patients with and without symptoms of neurotoxicity. Pediatr Blood Cancer 52:26–32
Lo Nogro L, Di Cataldo A, Schiliro G (2000) Acute neurotoxicity in children treated with B-lineage acute lymphatic leukemia (B ALL) treated with intermediate risk protocols. Med Pediatr Oncol 35:449–455
Rizzari C, Valsecchi MG, Aricò M, Conter V, Testi A, Barisone E, Casale F, Lo Nigro L, Rondelli R, Basso G, Santoro N, Masera G, Pediatrica Associazione Italiano Ematologia Oncologia (1993) Effect of protracted high dose l-Aspaginase given as a second exposure in the Berlin-Frankfort-Munster-based treatment: results of a randomized 9102 intermediate-risk childhood acute lymphatic leukemia study—a report from the Associazone Italiana Emetologia Oncologia. J Clin Oncol 19:1297–1303
Mennes M, Stiers P, Vandenbussche E, Vercruysse G, Uyttebroeck D, De Meyer G, Van Cool SW (2005) Attention and information processing in survivors of childhood acute lymphatic leukemia treated with chemotherapy alone. Pediatr Blood Cancer 44:479–486
Millot F, Suciu S, Philippe N, Children’s Leukemia Cooperative Group of the European Organization for Research and Treatment of Cancer et al (1993) Value of high dose cytarabine during interval therapy of a Berlin-Frankfurt-Munster based protocol in increased-risk children with acute lymphatic leukemia and lymphoblastic leukemia: results of the European organization for research and treatment of cancer 58881 randomized phase 111 trial. J Clin Oncol 19:1935–1942
Camitta B, Mahoney D, Leventhal B et al (1994) Intensive intravenous methotrexate and mercaptopurine treatment of higher-risk non-T, non-B acute lymphocytic leukemia: a Pediatric Oncology Group study. J Clin Oncol 12:1383–1389
Mahoney DH Jr, Shuster JJ, Nitschke R, Lauer SJ, Steuber CP, Winick N, Camitta B (1998) Acute neurotoxicity in children with B-precursor acute lymphoid leukemia: an association with intermediate-dose methotrexate and intrathecal triple therapy—a pediatric oncology group study. J Clin Oncol 16:1712–1722
Bell B, Abish S, Shuster J, Camitta B (1997) Neurotoxicity (NT) in children with standard-risk acute lymphoblastic leukemia (ALL) on Pediatric Oncology Group (POG) 9405. Blood 90:559a
Buizer AI, de Sonneville LM, van den Heuvel-Eibrink MM, Veerman AJ (2005) Chemotherapy and attention dysfunction in survivors of childhood acute lymphoblastic leukemia: effect of treatment intensity. Pediatr Blood Cancer 45:281–290
Cohen IJ (2007) Comparison of long-term neurocognitive outcomes in young children with acute lymphatic leukemia treated with cranial radiation or high-dose or very high-dose intravenous methotrexate. J Clin Oncol 25:734–735
Kamps WA, Bökkerink JP, Hakvoort-Cammel FG, Veerman AJ, Weening RS, van Wering ER, van Weerden JF, Hermans J, Slater R, van den Berg E, Kroes WG, van der Does-van den Berg A (2002) BFM-oriented treatment for children with acute lymphoblastic leukemia without cranial irradiation and treatment reduction for standard risk patients: result of DCLSG protocol ALL-8 (1991–1996). Leukemia 16:1099–1111
Veerman AJ, Kamps WA, van den Berg H, Dutch Childhood Oncology Group et al (2009) Dexamethasone-based therapy for childhood acute lymphoblastic leukemia: results of the prospective Dutch Childhood Oncology Group (DCOG) protocol ALL-9 (1997–2004). Lancet Oncol 10:957–966
Buendia MT, Lozano JM, Saurez GE, Saavendra C, Guevara G (2008) The impact of acute lymphatic leukemia on central nervous system results in Bogota Colombia. J Pedatr Hematol Oncol 30:643–650
Goren MP, Wright RK, Horowitz ME, Meyer WH (1986) Enhancement of methotrexate nephrotoxicity after cisplatin therapy. Cancer 58:2617–2621
Forster VJ, van Delft FW, Baird SF, Mair S, Skinner R, Halse C (2016) Drug interactions may be important risk factors for methotrexate neurotoxicity, particularly in pediatric leukemia patients. Cancer Chemother Pharmacol 78:1093–1096
Keefe BA, Capizzi RK, Rudnick SA (1982) Methotrexate cytotoxicity for L5178/Asn –lymphoblasts: relationship of dose and duration of exposure to tumor cell viability. Cancer Res 42:1641–1645
Shkalim-Zemer V, Ash S, Toledano H, Kollender Y, Issakov J, Yaniv I, Cohen IJ (2015) Highly effective reduced toxicity dose-intensive pilot protocol for non-metastatic limb osteogenic sarcoma (SCOS 89). Cancer Chemother Pharmacol 76:909–916
Shkalim Zemer V, Toladano H, Ash S, Cohen E, Yaniv I, Cohen IJ (2016) Factors affecting the upper limit of the methotrexate (MTX) levels achievable in children with brain tumors treated with high-dose intravenous methotrexate. J Pediatr Hematol Oncol 38:5544–5548
Mikkelsen TS, Sparreboom A, Cheng C, Zhou Y, Boyett JM, Raimondi SC, Panetta JC, Bowman WP, Sandlund JT, Pui CH, Relling MV, Evans WE (2011) Shortening infusion time for high-dose methotrexate alters antileukemic effects: a randomized prospective clinical trial. J Clin Oncol 29:1771–1778
Cohen IJ, Wolff JE (2014) How long can folinic acid rescue be delayed after high-dose methotrexate without toxicity? Pediatr Blood Cancer 61:7–10
Mahoney DH Jr, Shuster J, Nitschke R et al (1998) Intermediate-dose intravenous methotrexate with intravenous mercaptopurine is superior to repetitive low-dose methotrexate with intravenous mercaptopurine for children with lower-risk B lineage acute lymphoblastic leukemia: a PediatricOncology Group phase III trial. J Clin Oncol 16:246–25412
Djerassi I, Kim JS (1976) Methotrexate and citrovorum factor rescue in the management of childhood lymphosarcoma and reticulum cell sarcoma (non-Hodgkin’s lymphomas): prolonged unmaintained remissions. Cancer 38:1043–1051
Camitta B, Holcenberg JS (1978) Safety of delayed leucovorin “rescue” following high-dose methotrexate in children. Med Pediatr Oncol 5:55–59
Spiegler BJ, Kennedy K, Maze R, Greenberg ML, Weitzman S, Hitzler JK, Nathan PC (2006) Comparison of long term neurocognitive outcomes in young children with acute lymphoblastic leukemia treated with cranial radiation or high-dose or very high-dose intravenous methotrexate. J Clin Oncol 24:3858–3864
Balis FM, Savitch JL, Bleyer WA, Reaman GH, Poplack DG (1985) Remission induction of meningeal leukemia with high-dose intravenous methotrexate. J Clin Oncol 3:485–489
Nathan PC, Whitcom T, Pl Wolters, Steinberg SM, Balis FM, Brouwers P, Hunsberger S, Feusner J, Sather H, Miser J, Odom LF, Poplack D, Reaman G, Bleyer WA et al (2006) Very high-dose methotrexate [33.6 g/m(2)] as central nervous system preventive therapy for childhood acute lymphoblastic leukemia: results of National Cancer Institute/Children’s Cancer Group trials CCG-191P, CCG134P and CCG144P. Leuk Lymphoma 47:2488–2504
Von Stackelberg A, Yamanak J, Escherich G et al (2011) Conventional Reinduction/consolidation type therapy versus short course high intensity combination chemotherapy as post induction treatment for childrenwith relapsed acute lymphoblastic leukemia. Early results of study BFM ALL-REZ 2002. Blood 118:397
Joannon P, Oviedo I, Campell M, Tordecilla J (2004) High-dose methotrexate therapy of childhood acute lymphoblastic leukemia: lack of relation between serum methotrexate concentration and creatinine clearance. Pediatr Blood Cancer 43:17–22
Vermar S, Becker A, Bode U, Jaehde U (2003) Biochemical and clinical aspects of methotrexate neurotoxicity. Chemotherapy 49:92–104
Kingma A, Van Dommelen RI, Mooyaart EL, Wilmink JT, Deelman BG, Kamps WA (2002) No major cognitive impairment in young children with acute lymphatic leukemia using chemotherapy only: a prospective longitudinal study. J Pediatr Hematol Oncol 24:106–114
Rodgers J, Marckus R, Kearns P, Windebank K (2003) Attentional ability among survivors of leukemia treated without cranial irradiation. Arch Dis Child 88:147–150
Hann I, Vora A, Harrison R et al (2001) UK medical research council’s working party on childhood leukaemia. Determinants of outcome after intensified therapy of childhood lymphoblastic leukaemia: results from medical research council United Kingdom acute lymphatic leukaemia XI protocol. Br J Haematol 113:103–114
Patte C, Auperin A, Michon J, Société Française d’Oncologie Pédiatrique et al (2001) The Société Française d’Oncologie Pédiatrique LMB89 protocol: highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia. Blood 97:3370–3379
Mcallister LD, Doolittle NC, Guastadisegni PE, Kraemer DF, Lacy CA, Crossen JR, Neuwelt EA (2000) Cognitive outcomes and long term follow up results after enhanced chemotherapy delivery for primary central nervous system lymphoma. Neurosurgery 46:51–61
Edelmann MN, Daryani VM, Bishop MW, Liu W, Brinkman TM, Stewart CF, Mulrooney DA, Kimberg C, Ness KK, Cheung YT, Srivastava DK, Robison LL, Hudson MM, Krull KR (2016) Neurocognitive and patient reported outcomes in adult survivors of childhood osteosarcoma. JAMA Oncol 2:201–208
Bonda-Shkedi E, Weyl Ben Arush M, Kaplinsky C, Ash S, Goshen Y, Yaniv I, Cohen IJ (2013) The correlation between dose of folinic acid and neurotoxicity in children and adolescents treated for osteosarcoma with high-dose methotrexate (HDMTX): a neuropsychological and psychosocial study. J Pediatr Hematol Oncol 35:271–275
Sirotnak FM, Donsbach RC, Moccio DM, Dorick DM (1976) Biochemical and pharmacokinetic effects of leucovorin after high dose methotrexate in a murine leukemia model. Cancer Res 36:4679–4686
Cohen IJ (2003) Progression of osteosarcoma after high dose methotrexate: over rescue by folinic acid. Pediatr Hematol Oncol 20:579–581
Cohen IJ (2009) High-dose methotrexate is effective in osteosarcoma so what is the problem? J Pediatr Hematol Oncol 31:892–894
Toft N, Birgens H, Abrahamsson J et al (2016) Toxicity profile and treatment delays in NOPHO ALL2008 comparing adults and children with Philadelphia chromosome-negative acute lymphoblastic leukemia. Eur J Haematol 96:160–169
Jacola LM, Krull KR, Pui CH, Pei D, Cheng C, Reddick WE, Conklin HM (2016) Longitudinal assessment of neurocognitive outcomes in survivors of childhood acute lymphoblastic leukemia treated on a contemporary chemotherapy protocol. J Clin Oncol 34:1239–1247
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The author declares that have no conflict of interest.
Funding
No funding was received.
Ethical approval
This article does not contain any studies with human participants or animals performed by any of the authors.
Informed consent
Not applicable.
Rights and permissions
About this article
Cite this article
Cohen, I.J. Neurotoxicity after high-dose methotrexate (MTX) is adequately explained by insufficient folinic acid rescue. Cancer Chemother Pharmacol 79, 1057–1065 (2017). https://doi.org/10.1007/s00280-017-3304-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00280-017-3304-y